Bipolar Disorder in the Era of Precision Psychiatry: Biomarkers, Digital Innovations, and Global Challenges

Le résumé fourni par la source

Bipolar disorder (BD) is a severe, recurrent psychiatric illness characterized by episodes of mania, hypomania, and depression, with profound consequences for individuals, families, and societies. Affecting an estimated 1–2% of the global population, BD ranks among the top contributors to years lived with disability and premature mortality. High suicide risk, cognitive impairment, and substantial functional disability compound its impact, while comorbid conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD), and substance use disorders amplify diagnostic challenges and worsen prognosis. Diagnostic delay—often 6–10 years from illness onset—remains a major barrier, reflecting overlapping transdiagnostic symptoms and the absence of reliable biomarkers in routine clinical use. Over the past decade, advances in neuroscience and translational psychiatry have begun to reshape the landscape of BD research and care. A growing body of evidence implicates dysregulated circadian rhythms, immune-inflammatory pathways, mitochondrial dysfunction, and polygenic liability as key drivers of illness course. These insights are now converging with precision psychiatry initiatives that aim to integrate genomic, neuroimaging, and peripheral biomarker data into individualized treatment strategies. In parallel, the rapid growth of digital psychiatry and artificial intelligence–enabled tools provides unprecedented opportunities for real-time mood monitoring, early relapse detection, and personalized intervention delivery. Importantly, these technologies may bridge long-standing gaps in access to care, although concerns around privacy, equity, and algorithmic bias must be addressed. Therapeutic innovation has also accelerated, with evidence supporting the adjunctive use of anti-inflammatory and neuroprotective agents, alongside chronotherapeutic approaches that target circadian instability. These interventions complement, rather than replace, existing pharmacological and psychotherapeutic frameworks, reflecting a shift toward multimodal and mechanism-informed treatment paradigms. At a systems level, global mental health perspectives highlight persistent disparities in diagnosis and treatment, particularly in low- and middle-income countries where the treatment gap exceeds 70%. Policy reforms, equitable digital infrastructure, and culturally tailored care models will be essential to ensure that advances in precision psychiatry and therapeutics are accessible worldwide. This review synthesizes emerging insights across biological, clinical, technological, and policy domains, highlighting both achievements and unmet needs in BD research and care. By emphasizing biomarkers, digital psychiatry, novel therapeutics, and global health imperatives, it outlines a roadmap for translating discovery into improved outcomes, ultimately moving toward individualized, equitable, and sustainable care for those living with bipolar disorder.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.